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As understanding has grown about what happens when heart muscle cells die en masse after a heart attack, so has the development of treatments aimed at avoiding the loss or failure of cardiovascular function. These treatments include stem cell transplantation. The first pre-clinical and clinical experiences in stem cell transplantation were reported around a decade ago. 1, 2 However, and although the field has moved quickly in these years, the most important questions-the 'cell product' to be used, delivery method, outcome measurement, organizational problems, and funding-remain unanswered.
The quest for the best cell type has been wheeled around from bedside to bench and back again. 3 The ideal cell type should be The study by Bai et al. 4 also confirms that cultured and freshly isolated ASCs have different cell surface characteristics, which are homogeneous in cultured ASCs showing a fibroblast-like morphology but heterogeneous in freshly isolated ASCs containing different populations, including functional endothelial cells ( Table 1) . In this study, the rigorous use of magnetic resonance imaging to examine the long-term effect of both cultured and freshly isolated ASCs revealed a functional improvement in left ventricular function compared with mice intramyocardially injected with phosphate-buffered saline alone (controls). Freshly isolated ASCs induced a similar effect in the injured hearts when compared with cultured ASCs. Thus, this study does not enable us to determine which ASC products are better or which specific freshly isolated adipose tissue-derived cell type mediates the beneficial effect. As in other studies, this area of uncertainty warrants further study. However, the advantages of using freshly isolated ASCs obviates the need for prior cell expansion in vitro, thus allowing for immediate autologous cell transplantation at the time of an acute infarction.
ASCs: mechanism of action
Both freshly isolated and cultured ASCs appear to be a representative example of plasticity, because of their outstanding ability to generate a wide range of cell types from different organs. Some authors have suggested that the mechanism by which bone marrow-derived cells change their phenotype might be a process of in vivo fusion of stem cells with differentiated host cells. 6 It is remarkable that previous studies using murine cultured ASCs in a chronic infarction model failed to detect any injected cells 30 days after transplantation 12 (the survival of freshly isolated ASCs in this setting has yet to be elucidated). Therefore, we could reasonably propose that the experimental model of acute myocardial infarction is a suitable environment for ASCs to survive and reach a cardiac phenotype, as shown in the study of Bai and colleagues and in other recently published studies, 8 whereas the harsh environment inherent to the chronic infarction model (e.g. fibrotic areas, mechanical forces) is probably responsible for the limited engraftment observed. It is well known that both ischaemia and reperfusion are accompanied by an inflammatory reaction in which neutrophils and monocytes are recruited from the bloodstream as part of the cell-mediated inflammatory response. The factors (cytokines and growth factors) that control the complex inflammatory process may also guide the behaviour of ASCs in tissue repair. However, to date, it is difficult to establish the role and influence of each cytokine, because their effects are time and location dependent. The intensity of homing and survival, which also depend on the transfer method, may vary. Direct intramyocardial delivery significantly increases the number of cells introduced into the heart in comparison with other intravascular methods. 13 Bai et al. showed that intramyocardially injected cultured ASCs were retained in the heart and did not migrate in significant numbers to other organs or tissues up to 4 months after transplantation. Post-mortem histological analysis confirmed this finding, and the presence of freshly isolated ASCs was not found in other organs. Until now, molecular imaging with radioactively labelled stem cells showed that the percentage of cells homing to the heart was low, with other organs (kidney, liver, and spleen) receiving the vast majority of progenitors, both in animal models 14, 15 and in humans. 16 The contrast between heart-homing ASCs and bone marrow-derived stem cells suggests that ASCs transdifferentiate into cardiomyocytes and vascular cells, as shown by Bai et al., and that further paracrine factors secreted by these cells are also fundamental for cell retention.
ASCs: therapeutic applications
Lastly, the observation that transplantation of freshly isolated ASCs into ischaemic hearts promotes cardiac function as well as cultured ASC transplants do has obvious therapeutic consequences for human cardiac repair (Figure 1) . 
Editorial in the fields of plastic and reconstructive surgery and digestive surgery, 17 -19 no cardiovascular clinical trials on ASCs have been published to date. Nevertheless, two ongoing trials-APOLLO and PRECISE-are exploring the safety, feasibility, and efficacy of freshly isolated ASCs with the Cellution TM system (Cytori Therapeutic Inc.) in both acute myocardial infarction and chronic myocardial ischaemia. Both trials have just completed enrolment and are finishing follow-up. PRECISE is a prospective, double-blind, Figure 1 An example of the hypothetical clinical use of adipose-tissue derived stem cells. After abdominal liposuction, fat tissue could be digested and centrifuged to obtain stem cells, allowing for immediate autologous cell transplantation (e.g. at the time of an acute infarction), or fat tissue could be cultured and expanded and consequently delete their delivery (e.g. in the scenario of chronic ischaemic heart disease). Both type of cells, freshly isolated and cultured, present different cell surface characteristics. Several routes of cell delivery could be used: intracoronary administration of cells, catheter-based delivery, direct intramyocardial injection of cells through the endocardium (guided by fluoroscopy and/or electromechanical mapping), or direct intramyocardial injection through the epicardium during open chest cardiac surgery. Editorial randomized, placebo-controlled, sequential dose-escalation trial randomizing patients with end-stage coronary artery disease not amenable to revascularization and with moderate-severe left ventricular dysfunction to receive freshly isolated ASCs or placebo in a 3:1 ratio. The cells are delivered via transendocardial injections after left ventricle electromechanical mapping with the NOGA XP TM delivery system (BDS). APOLLO aims to investigate the same source of freshly isolated ASCs, although in patients with acute myocardial infarction and left ventricular ejection fraction impairment. It is also a prospective, double-blind, randomized, placebo-controlled, sequential dose-escalation trial in which ASCs are delivered through intracoronary infusion after appropriate infarct-related artery repair with stent implantation.
Several scientific and medical questions related to ASCs have yet to be answered before this approach can be applied in routine clinical practice. First, further research is necessary to establish the ideal subpopulation for cardiovascular repair, as well as the isolation and culture processes to be adopted. Therefore, consensus much be reached on the cell terminology to be used when describing multipotent precursor cells from adipose tissue stroma. Secondly, the immunogenicity of ASCs is worthy of extensive research-class I and II major histocompatibility complexes are expressed in only 1% of ASCs, and, therefore, it has been hypothesized that these could behave as universal donor cells and could be used for autologous and allogenic transplantation. In this sense, the study by Bai et al. could have provided data on inflammatory reactions due to graft rejection or the immunosuppressive regimens, if any, used in their experiment. Finally, the possibility of adverse events must be ruled out. The two main concerns are haemostasis when harvesting adipose tissue in patients with acute myocardial infarction who are on antiplatelet and anticoagulant treatment and the exceptional chance of long-term tumour development. 20 No cases of arrhythmia have been reported in any of the studies performed to date. To summarize, we think that human adipose tissue is a novel promising alternative source of stem cells for cardiovascular repair that, as shown by Bai et al., has revealed encouraging results in the pre-clinical field. Nevertheless, the applicability of these results to humans is an important issue. The ongoing PRECISE and APOLLO trials will shed light on the safety and efficacy issues of the cardiovascular application of these exciting cells. Fat years for cardiac stem cell therapy are on the way.
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